Full Breakdown
Personalized mRNA Vaccine Combined with KEYTRUDA Cuts Melanoma Recurrence Risk by Nearly Half in Five-Year Follow-Up
6/14/2026, 6:39:32 AM
Breakthrough Phase 2b Study Reduces Melanoma Recurrence
The phase 2b KEYNOTE-942 trial, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27, evaluated 157 patients with high-risk stage 3 or 4 melanoma whose tumors had been surgically removed. Participants were randomized to receive either the personalized mRNA vaccine intismeran autogene plus pembrolizumab (KEYTRUDA) or pembrolizumab alone. After approximately five years, the combination therapy lowered the risk of melanoma recurrence or death by 49 % relative to pembrolizumab monotherapy. Researchers described the benefit as “sustained and durable over time.”
Development of Intismeran Autogene: A Personalized mRNA Approach
Intismeran autogene is an injectable vaccine engineered from mutations identified in each patient’s own tumor. By encoding these tumor-specific antigens in messenger RNA, the vaccine aims to train the immune system to recognize and destroy residual cancer cells after surgery.
Key Researchers and Corporate Leaders
- Kyle Holen, MD – Senior Vice President and Head of Development, Oncology and Therapeutics, Moderna.
- Dr. Marjorie Green – Senior Vice President and Head of Oncology, Global Clinical Development, Merck Research Laboratories.
- Unnamed study investigators who conducted the KEYNOTE-942 analysis.
Trial Data and Safety Profile
- Participants: 157 high-risk melanoma patients.
- Efficacy: 49 % reduction in recurrence or death risk with the vaccine-KEYTRUDA combo.
- Common adverse events: fatigue, injection-site pain, chills, fever, headache.
- Safety assessment: The regimen was described as “well-tolerated” with a “manageable” safety profile; no new long-term safety concerns or severe vaccine-related adverse events were reported.
Clinical Implications and Future Research
The findings represent a “meaningful milestone” for patients facing a substantial risk of post-surgical melanoma recurrence. The combination therapy is now advancing to a phase 3 trial, the final confirmation stage, while Merck and Moderna also anticipate results from the late-stage INTerpath trial investigating the vaccine in additional hard-to-treat cancers.
Official Statements & Responses
- Kyle Holen emphasized the “potential of a prolonged benefit … in patients with resected high-risk melanoma” and reaffirmed Moderna’s commitment to oncology, noting that the outcomes “illustrate mRNA’s potential in cancer care.”
- Dr. Marjorie Green highlighted the “significant risk of recurrence following surgery” and called the study’s long-term data a “meaningful milestone” demonstrating the vaccine’s longer-term potential when paired with KEYTRUDA.
Conflicting Reports & Gaps
The sources present a consistent set of efficacy and safety data; no contradictory findings or identified information gaps were reported.
Verbatim Quotes
- “sustained and durable over time.” — Study researchers
- “well-tolerated” with a “manageable” safety profile. — Study researchers
- “potential of a prolonged benefit … in patients with resected high-risk melanoma.” — Kyle Holen, MD, Moderna senior vice president and head of development, oncology and therapeutics
- “We continue to invest in our platform in oncology because of encouraging outcomes like these, which illustrate mRNA’s potential in cancer care,” — Kyle Holen, MD
- “ "As such, demonstrating the longer-term potential of intismeran autogene and KEYTRUDA to reduce the risk of recurrence for certain patients with melanoma is a meaningful milestone," she said.” — Dr. Marjorie Green, Merck senior vice president and head of oncology, global clinical development
What’s Next
The phase 3 trial of intismeran autogene plus KEYTRUDA is underway, with results expected to confirm the durability of the observed benefit. Concurrently, the INTerpath trial’s late-stage data will provide additional insight into the vaccine’s applicability across other difficult-to-treat malignancies.
